Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine

Theisen, Frank; Linden, André; König, IR; Martı́n, Miguel Ángel; Remschmidt, Helmut; Hebebrand, Johannes

doi:10.1007/s00702-002-0792-6

Cited by 102 publications

(31 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Altered cognitive functions can independently affect the control of appetite [11]. Treatment with both clozapine and olanzapine have been temporally associated with food craving and binge eating [12,13]. …”

Section: Introductionmentioning

confidence: 99%

The potential role of appetite in predicting weight changes during treatment with olanzapine

et al. 2010

View full text Add to dashboard Cite

BackgroundClinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite.MethodsData were used from adult patients for whom both appetite and weight data were available from 4 prospective, 12- to 24-week clinical trials. Patients' appetites were assessed with Eating Behavior Assessment (EBA, Study 1), Platypus Appetite Rating Scale (PARS, Study 2), Eating Inventory (EI, Study 3), Food Craving Inventory (FCI, Study 3), and Eating Attitude Scale (EAS, Study 4).ResultsIn Studies 1 (EBA) and 4 (EAS), patients who reported overall score increases on appetite scales, indicating an increase in appetite, experienced the greatest overall weight gains. However, in Studies 2 (PARS) and 3 (EI, FCI), patients who reported overall score increases on appetite scales did not experience greater weight changes than patients not reporting score increases. Early weight changes (2-4 weeks) were more positively correlated with overall weight changes than early or overall score changes on any utilized appetite assessment scale. No additional information was gained by adding early appetite change to early weight change in correlation to overall weight change.ConclusionsEarly weight changes may be a more useful predictor for long-term weight changes than early score changes on appetite assessment scales.Clinical Trials RegistrationThis report represents secondary analyses of 4 clinical studies. Studies 1, 2, and 3 were registered at http://clinicaltrials.gov/ct2/home, under NCT00190749, NCT00303602, and NCT00401973, respectively. Study 4 predates the registration requirements for observational studies that are not classified as category 1 observational studies.

show abstract

Section: Introductionmentioning

confidence: 99%

The potential role of appetite in predicting weight changes during treatment with olanzapine

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The mechanisms underlying antipsychotic-induced weight gain, however, are poorly understood. Plausible explanations include reduced physical activity, metabolic changes resulting in reduced calorie burn-off, stronger appetite resulting in increased food intake,5,6 and differences in receptor binding profiles 7. …”

Section: Introductionmentioning

confidence: 99%

The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats

Wilmsdorff

Bouvier

Henning

et al. 2010

Clinics

View full text Add to dashboard Cite

OBJECTIVES:The aim of our study was to investigate the impact of typical and atypical antipsychotic drugs on leptin concentration in blood and changes in the receptor expression in the hypothalamus of male Wistar rats.METHODS:From the age of 13 to 18 weeks, three groups of 20 animals were fed an average dose of 3.5 ± 0.03 mg/ kg body weight (BW) haloperidol; 30.6 ± 0.22 mg/kg BW clozapine; or 14.9 ± 0.13 mg/kg BW ziprasidone in ground food pellets containing 15% fat. Twenty control animals received no drugs. Blood samples were taken at week 14, 16, and 19. Locomotor activity and exploratory behavior were measured using the alcove test at weeks 15 and 17. The expression of the hypothalamic leptin receptor in rat brains was determined by using a Western blot.RESULTS:Rats medicated with haloperidol and ziprasidone showed a significantly decreased percentage weight gain and food consumption. We observed no differences in the alcove test, but locomotor activity was significantly reduced in the haloperidol group. Except for rats in the clozapine and ziprasidone groups, after 2 weeks of drug application, we found no changes in the leptin blood concentrations among the four groups or animals within each group. Moreover, we did not find specific differences in hypothalamic leptin receptor expression among the groups.CONCLUSION:We concluded that in male Wistar rats during this treatment period, the tested drugs did not act directly on the leptin regulatory system. We recommend further studies using long-term treatment of different rat strains.

show abstract

“…Individuals with at least one ≥7R allele showed reduced binding affinities and receptor densities for dopamine neurotransmission [134]. This VNTR has also been associated with increased food intake in patients treated with DRD4-related antipsychotics [135], and with addictive behaviors [136]. In some studies, DRD4 VNTR and higher BMI correlation was shown [137, 138].…”

Section: Main Textmentioning

confidence: 99%

The association of insertions/deletions (INDELs) and variable number tandem repeats (VNTRs) with obesity and its related traits and complications

Say

2017

J Physiol Anthropol

View full text Add to dashboard Cite

BackgroundDespite the fact that insertions/deletions (INDELs) are the second most common type of genetic variations and variable number tandem repeats (VNTRs) represent a large portion of the human genome, they have received far less attention than single nucleotide polymorphisms (SNPs) and larger forms of structural variation like copy number variations (CNVs), especially in genome-wide association studies (GWAS) of complex diseases like polygenic obesity. This is exemplified by the vast amount of review papers on the role of SNPs and CNVs in obesity, its related traits (like anthropometric measurements, biochemical variables, and eating behavior), and its related complications (like hypertension, hypertriglyceridemia, hypercholesterolemia, and insulin resistance—collectively known as metabolic syndrome). Hence, this paper reviews the types of INDELs and VNTRs that have been studied for association with obesity and its related traits and complications.Main body of the abstractThese INDELs and VNTRs could be found in the obesity loci or genes from the earliest GWAS and candidate gene association studies, like FTO, genes in the leptin–proopiomelanocortin pathway, and UCP2/3. Given the important role of the brain serotonergic and dopaminergic reward system in obesity susceptibility, the association of INDELs and VNTRs in these neurotransmitters’ metabolism and transport genes with obesity is also reviewed. Next, the role of INS VNTR in obesity and its related traits is questionable, since recent large-scale studies failed to replicate the earlier positive associations. As obesity results in chronic low-grade inflammation of the adipose tissue, the proinflammatory cytokine gene IL1RA and anti-inflammatory cytokine gene IL4 have VNTRs that are implicated in obesity. A systemic proinflammatory state in combination with activation of the renin–angiotensin system and decreased nitric oxide bioavailability as found in obesity leads to endothelial dysfunction. This explains why VNTR and INDEL in eNOS and ACE, respectively, could be predisposing factors of obesity. Finally, two novel genes, DOCK5 and PER3, which are involved in the regulation of the Akt/MAPK pathway and circadian rhythm, respectively, have VNTRs and INDEL that might be associated with obesity.Short conclusionIn conclusion, INDELs and VNTRs could have important functional consequences in the pathophysiology of obesity, and research on them should be continued to facilitate obesity prediction, prevention, and treatment.

show abstract

Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine

Cited by 102 publications

References 22 publications

The potential role of appetite in predicting weight changes during treatment with olanzapine

The potential role of appetite in predicting weight changes during treatment with olanzapine

The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats

The association of insertions/deletions (INDELs) and variable number tandem repeats (VNTRs) with obesity and its related traits and complications

Contact Info

Product

Resources

About